nach oben

Current Treatment Options in Pediatrics

Erschienen in:

01.06.2019 | Pediatric Nephrology (BP Dixon and E Nehus, Section Editors)

Chronic Kidney Disease in Children: Risk-Based Stratification and Treatment

verfasst von: Darcy K. Weidemann, MD, MHS, Bradley A. Warady, MD

Erschienen in: Current Treatment Options in Pediatrics | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

This paper provides a review of the epidemiology, classification, risk-based stratification, and identification of traditional and novel risk factors for chronic kidney disease (CKD) progression in children. Current treatment strategies designed to halt progression and best practices regarding vascular access preservation are discussed.

Recent findings

Substantial progress in CKD diagnosis has been made, particularly in the refinement of glomerular filtration rate (GFR) estimating equations in children. A number of new risk factors for CKD progression are described, including genetic underpinnings of CKD. Efforts designed to risk-stratify those children at highest risk for progression to ESRD and to define modifiable risk factors have been undertaken by collaborative research initiatives.

Summary

The management of pediatric CKD comprises appropriate diagnosis and classification of CKD severity through the use of updated eGFR estimating equations, and amelioration of existing risk factors for progression. The most important factors, hypertension and proteinuria, are validated endpoints for treatment with medications that target renin-angiotensin-aldosterone system blockade. Optimal blood pressure management is also essential to limit the frequency of cardiovascular disease. Several multicenter collaborative studies have shed light on the myriad of comorbidities experienced by children with CKD, in addition to elucidating risk determinants for CKD progression.

Hazzan AD, Halinski C, Agoritsas S, Fishbane S, DeVita MV. Epidemiology and challenges to the management of advanced CKD. Adv Chronic Kidney Dis. 2016;23(4):217–21. https://doi.org/10.1053/j.ackd.2016.04.005.CrossRefPubMed

Obrador GT, Pereira BJ, Kausz AT. Chronic kidney disease in the United States: an underrecognized problem. Semin Nephrol. 2002;22(6):441–8.CrossRefPubMed

Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–72. https://doi.org/10.1016/S0140-6736(13)60687-X.CrossRefPubMed

Harambat J, van Stralen KJ, Kim JJ, Tizard EJ. Epidemiology of chronic kidney disease in children. Pediatr Nephrol. 2012;27(3):363–73. https://doi.org/10.1007/s00467-011-1939-1.CrossRefPubMed

• Saran R, Robinson B, Abbott KC, Agodoa LYC, Bhave N, Bragg-Gresham J, et al. US renal data system 2017 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2018;71(3S1):A7. https://doi.org/10.1053/j.ajkd.2018.01.002 Annual data report of the United States Renal Data System which is a national registry of ESRD patients, and provides some of the highest-quality and most comprehensive epidemiological data regarding adults and children with ESRD.CrossRefPubMedPubMedCentral

Mitsnefes MM. Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol. 2012;23(4):578–85. https://doi.org/10.1681/ASN.2011111115.CrossRefPubMedPubMedCentral

Parekh RS, Carroll CE, Wolfe RA, Port FK. Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr. 2002;141(2):191–7. https://doi.org/10.1067/mpd.2002.125910.CrossRefPubMed

Baek HS, Kang HG, Choi HJ, Cheong HI, Ha IS, Han KH, et al. Health-related quality of life of children with pre-dialysis chronic kidney disease. Pediatr Nephrol. 2017;32(11):2097–105. https://doi.org/10.1007/s00467-017-3721-5.CrossRefPubMed

Greenbaum LA, Warady BA, Furth SL. Current advances in chronic kidney disease in children: growth, cardiovascular, and neurocognitive risk factors. Semin Nephrol. 2009;29(4):425–34. https://doi.org/10.1016/j.semnephrol.2009.03.017.CrossRefPubMedPubMedCentral

10.

Shroff R, Ledermann S. Long-term outcome of chronic dialysis in children. Pediatr Nephrol. 2009;24(3):463–74. https://doi.org/10.1007/s00467-007-0700-2.CrossRefPubMedPubMedCentral

11.

Kidney Disease Improving Global Outcomes. Chapter 1: definition and classification of CKD. Kidney Int Suppl. 2013;3(1):19–62. https://doi.org/10.1038/kisup.2012.64.CrossRef

12.

Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, et al. National Kidney Foundation’s kidney disease outcomes quality initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics. 2003;111(6 Pt 1):1416–21.CrossRefPubMed

13.

Weidemann DK, Warady BW. Chapter 48: kidney diseases in infants and children. In: Gilbert SJ, Weiner DE, editors. National Kidney Foundation’s primer on kidney diseases. 7th ed. Philadelphia, PA: Elsevier/Saunders; 2017.

14.

Geary DF, Schaefer F. Comprehensive pediatric nephrology. Philadelphia, PA: Mosby/Elsevier; 2008.

15.

Ardissino G, Dacco V, Testa S, Bonaudo R, Claris-Appiani A, Taioli E, et al. Epidemiology of chronic renal failure in children: data from the ItalKid project. Pediatrics. 2003;111(4 Pt 1):e382–7.CrossRefPubMed

16.

Staples AO, Greenbaum LA, Smith JM, Gipson DS, Filler G, Warady BA, et al. Association between clinical risk factors and progression of chronic kidney disease in children. Clin J Am Soc Nephrol. 2010;5(12):2172–9. https://doi.org/10.2215/CJN.07851109.CrossRefPubMedPubMedCentral

17.

Wong CJ, Moxey-Mims M, Jerry-Fluker J, Warady BA, Furth SL. CKiD (CKD in children) prospective cohort study: a review of current findings. Am J Kidney Dis. 2012;60(6):1002–11. https://doi.org/10.1053/j.ajkd.2012.07.018.CrossRefPubMedPubMedCentral

18.

• Mian AN, Schwartz GJ. Measurement and estimation of glomerular filtration rate in children. Adv Chronic Kidney Dis. 2017;24(6):348–56. https://doi.org/10.1053/j.ackd.2017.09.011 Comprehensive review examining measurement and estimation of GFR in children, with particular attention to historical methods, thorough review of contemporary estimating equations for children, and discussion on refinement and limitations of equations.CrossRefPubMedPubMedCentral

19.

Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. 1976;58(2):259–63.PubMed

20.

Counahan R, Chantler C, Ghazali S, Kirkwood B, Rose F, Barratt TM. Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch Dis Child. 1976;51(11):875–8.CrossRefPubMedPubMedCentral

21.

•• Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629–37. https://doi.org/10.1681/ASN.2008030287 High-impact paper which provides a new GFR estimating equation for children with CKD derived from 349 children enrolled in the Chronic Kidney Disease in Children (CKiD) study based on measured GFR using the plasma disappearance of iohexol; current GFR estimating equation recommended for clinical and research applications.CrossRefPubMedPubMedCentral

22.

Schwartz GJ, Schneider MF, Maier PS, Moxey-Mims M, Dharnidharka VR, Warady BA, et al. Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. Kidney Int. 2012;82(4):445–53. https://doi.org/10.1038/ki.2012.169.CrossRefPubMedPubMedCentral

23.

Fadrowski JJ, Neu AM, Schwartz GJ, Furth SL. Pediatric GFR estimating equations applied to adolescents in the general population. Clin J Am Soc Nephrol. 2011;6(6):1427–35. https://doi.org/10.2215/CJN.06460710.CrossRefPubMedPubMedCentral

24.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRefPubMedPubMedCentral

25.

Ng DK, Schwartz GJ, Schneider MF, Furth SL, Warady BA. Combination of pediatric and adult formulas yield valid glomerular filtration rate estimates in young adults with a history of pediatric chronic kidney disease. Kidney Int. 2018;94(1):170–7. https://doi.org/10.1016/j.kint.2018.01.034.CrossRefPubMedPubMedCentral

26.

Pottel H, Hoste L, Martens F. A simple height-independent equation for estimating glomerular filtration rate in children. Pediatr Nephrol. 2012;27(6):973–9. https://doi.org/10.1007/s00467-011-2081-9.CrossRefPubMed

27.

Pottel H. Measuring and estimating glomerular filtration rate in children. Pediatr Nephrol. 2017;32(2):249–63. https://doi.org/10.1007/s00467-016-3373-x.CrossRefPubMed

28.

den Bakker E, Gemke R, Pottel H, van Wijk JAE, Hubeek I, Stoffel-Wagner B, et al. Estimation of GFR in children using rescaled beta-trace protein. Clin Chim Acta. 2018;486:259–64. https://doi.org/10.1016/j.cca.2018.08.021.CrossRef

29.

Wuhl E, van Stralen KJ, Verrina E, Bjerre A, Wanner C, Heaf JG, et al. Timing and outcome of renal replacement therapy in patients with congenital malformations of the kidney and urinary tract. Clin J Am Soc Nephrol. 2013;8(1):67–74. https://doi.org/10.2215/CJN.03310412.CrossRefPubMed

30.

• Warady BA, Abraham AG, Schwartz GJ, Wong CS, Munoz A, Betoko A, et al. Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: the chronic kidney disease in children (CKiD) cohort. Am J Kidney Dis. 2015;65(6):878–88. https://doi.org/10.1053/j.ajkd.2015.01.008 Prospective evaluation of 496 CKiD participants examining risk factors for rapid progression to composite event of RRT or 50% decline in GFR which could that important predictors for progression include proteinuria, hypertension, and hypoalbuminemia for both glomerular and nonglomerular patients, with additional risk factors of dyslipidemia, male gender, and anemia in the non-glomerular group.CrossRefPubMedPubMedCentral

31.

Fathallah-Shaykh SA, Flynn JT, Pierce CB, Abraham AG, Blydt-Hansen TD, Massengill SF, et al. Progression of pediatric CKD of nonglomerular origin in the CKiD cohort. Clin J Am Soc Nephrol. 2015;10(4):571–7. https://doi.org/10.2215/CJN.07480714.CrossRefPubMedPubMedCentral

32.

Furth SL, Pierce C, Hui WF, White CA, Wong CS, Schaefer F, et al. Estimating time to ESRD in children with CKD. Am J Kidney Dis. 2018;71(6):783–92. https://doi.org/10.1053/j.ajkd.2017.12.011.CrossRefPubMedPubMedCentral

33.

Oliveira EA, Mak RH. Progression of chronic kidney disease in children - role of glomerular hemodynamics and interstitial fibrosis. Curr Opin Pediatr. 2018;30(2):220–7. https://doi.org/10.1097/MOP.0000000000000594.CrossRefPubMed

34.

Flynn JT, Mitsnefes M, Pierce C, Cole SR, Parekh RS, Furth SL, et al. Blood pressure in children with chronic kidney disease: a report from the chronic kidney disease in children study. Hypertension. 2008;52(4):631–7. https://doi.org/10.1161/HYPERTENSIONAHA.108.110635.CrossRefPubMed

35.

Furth SL, Abraham AG, Jerry-Fluker J, Schwartz GJ, Benfield M, Kaskel F, et al. Metabolic abnormalities, cardiovascular disease risk factors, and GFR decline in children with chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(9):2132–40. https://doi.org/10.2215/CJN.07100810.CrossRefPubMedPubMedCentral

36.

Samuels J, Ng D, Flynn JT, Mitsnefes M, Poffenbarger T, Warady BA, et al. Ambulatory blood pressure patterns in children with chronic kidney disease. Hypertension. 2012;60(1):43–50. https://doi.org/10.1161/HYPERTENSIONAHA.111.189266.CrossRefPubMed

37.

Barletta GM, Pierce C, Mitsnefes M, Samuels J, Warady BA, Furth S, et al. Is blood pressure improving in children with chronic kidney disease? A Period Anal Hyperten. 2018;71(3):444–50. https://doi.org/10.1161/HYPERTENSIONAHA.117.09649.CrossRef

38.

Ardissino G, Testa S, Dacco V, Vigano S, Taioli E, Claris-Appiani A, et al. Proteinuria as a predictor of disease progression in children with hypodysplastic nephropathy. Data from the Ital kid project. Pediatr Nephrol. 2004;19(2):172–7. https://doi.org/10.1007/s00467-003-1268-0.CrossRefPubMed

39.

Ishikura K, Uemura O, Hamasaki Y, Ito S, Wada N, Hattori M, et al. Progression to end-stage kidney disease in Japanese children with chronic kidney disease: results of a nationwide prospective cohort study. Nephrol Dial Transplant. 2014;29(4):878–84. https://doi.org/10.1093/ndt/gfu012.CrossRefPubMed

40.

Wong CS, Pierce CB, Cole SR, Warady BA, Mak RH, Benador NM, et al. Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study. Clin J Am Soc Nephrol. 2009;4(4):812–9. https://doi.org/10.2215/CJN.01780408.CrossRefPubMedPubMedCentral

41.

•• Wuhl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, et al. For the ESCAPE trial group. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009;361(17):1639–50. https://doi.org/10.1056/NEJMoa0902066 Seminal paper and one of few interventional trials in pediatric CKD which demonstrated the importance of strict blood pressure control in children with CKD to delay progression.CrossRefPubMed

42.

• Ruggajo P, Skrunes R, Svarstad E, Skjaerven R, Reisaether AV, Vikse BE. Familial Factors, Low Birth Weight, and Development of ESRD: A Nationwide Registry Study. Am J Kidney Dis. 2016;67(4):601–8. https://doi.org/10.1053/j.ajkd.2015.11.015 Retrospective registry-based national birth cohort registry of Norway linked to a national database of ESRD patients which revealed that a history of low birth weight and small for gestational age were associated with a higher risk for ESRD in the first 40 years of life.CrossRefPubMed

43.

Abitbol CL, Chandar J, Rodriguez MM, Berho M, Seeherunvong W, Freundlich M, et al. Obesity and preterm birth: additive risks in the progression of kidney disease in children. Pediatr Nephrol. 2009;24(7):1363–70. https://doi.org/10.1007/s00467-009-1120-2.CrossRefPubMed

44.

Schreuder MF, Nauta J. Prenatal programming of nephron number and blood pressure. Kidney Int. 2007;72(3):265–8. https://doi.org/10.1038/sj.ki.5002307.CrossRefPubMed

45.

Gonzalez Celedon C, Bitsori M, Tullus K. Progression of chronic renal failure in children with dysplastic kidneys. Pediatr Nephrol. 2007;22(7):1014–20. https://doi.org/10.1007/s00467-007-0459-5.CrossRefPubMed

46.

Ardissino G, Testa S, Dacco V, Paglialonga F, Vigano S, Felice-Civitillo C, et al. Puberty is associated with increased deterioration of renal function in patients with CKD: data from the ItalKid project. Arch Dis Child. 2012;97(10):885–8. https://doi.org/10.1136/archdischild-2011-300685.CrossRefPubMed

47.

Gunta SS, Mak RH. Is obesity a risk factor for chronic kidney disease in children? Pediatr Nephrol. 2013;28(10):1949–56. https://doi.org/10.1007/s00467-012-2353-z.CrossRefPubMed

48.

Rodenbach KE, Schneider MF, Furth SL, Moxey-Mims MM, Mitsnefes MM, Weaver DJ, et al. Hyperuricemia and progression of CKD in children and adolescents: the chronic kidney disease in children (CKiD) cohort study. Am J Kidney Dis. 2015;66(6):984–92. https://doi.org/10.1053/j.ajkd.2015.06.015.CrossRefPubMedPubMedCentral

49.

Weidemann DK, Weaver VM, Fadrowski JJ. Toxic environmental exposures and kidney health in children. Pediatr Nephrol. 2016;31(11):2043–54. https://doi.org/10.1007/s00467-015-3222-3.CrossRefPubMed

50.

Staples A, Wong C. Risk factors for progression of chronic kidney disease. Curr Opin Pediatr. 2010;22(2):161–9. https://doi.org/10.1097/MOP.0b013e328336ebb0.CrossRefPubMedPubMedCentral

51.

Tullus K. Dyslipidemia in children with CKD: should we treat with statins? Pediatr Nephrol. 2012;27(3):357–62. https://doi.org/10.1007/s00467-011-1872-3.CrossRefPubMed

52.

Harambat J, Kunzmann K, Azukaitis K, Bayazit AK, Canpolat N, Doyon A, et al. Metabolic acidosis is common and associates with disease progression in children with chronic kidney disease. Kidney Int. 2017;92(6):1507–14. https://doi.org/10.1016/j.kint.2017.05.006.CrossRefPubMed

53.

Shroff R, Aitkenhead H, Costa N, Trivelli A, Litwin M, Picca S, et al. Normal 25-hydroxyvitamin D levels are associated with less proteinuria and attenuate renal failure progression in children with CKD. J Am Soc Nephrol. 2016;27(1):314–22. https://doi.org/10.1681/ASN.2014090947.CrossRefPubMed

54.

Portale AA, Wolf MS, Messinger S, Perwad F, Juppner H, Warady BA, et al. Fibroblast growth factor 23 and risk of CKD progression in children. Clin J Am Soc Nephrol. 2016;11(11):1989–98. https://doi.org/10.2215/CJN.02110216.CrossRefPubMedPubMedCentral

55.

Greenberg JH, Kakajiwala A, Parikh CR, Furth S. Emerging biomarkers of chronic kidney disease in children. Pediatr Nephrol. 2018;33(6):925–33. https://doi.org/10.1007/s00467-017-3701-9.CrossRefPubMed

56.

Backes Y, van der Sluijs KF, Mackie DP, Tacke F, Koch A, Tenhunen JJ, et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med. 2012;38(9):1418–28. https://doi.org/10.1007/s00134-012-2613-1.CrossRefPubMedPubMedCentral

57.

Schaefer F, Trachtman H, Wuhl E, Kirchner M, Hayek SS, Anarat A, et al. Association of serum soluble urokinase receptor levels with progression of kidney disease in children. JAMA Pediatr. 2017;171(11):e172914. https://doi.org/10.1001/jamapediatrics.2017.2914.CrossRefPubMedPubMedCentral

58.

Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med. 2013;369(23):2183–96. https://doi.org/10.1056/NEJMoa1310345.CrossRefPubMedPubMedCentral

59.

Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329(5993):841–5. https://doi.org/10.1126/science.1193032.CrossRefPubMedPubMedCentral

60.

Reidy KJ, Hjorten R, Parekh RS. Genetic risk of APOL1 and kidney disease in children and young adults of African ancestry. Curr Opin Pediatr. 2018;30(2):252–9. https://doi.org/10.1097/MOP.0000000000000603.CrossRefPubMedPubMedCentral

61.

Ng DK, Robertson CC, Woroniecki RP, Limou S, Gillies CE, Reidy KJ, et al. APOL1-associated glomerular disease among African-American children: a collaboration of the chronic kidney disease in children (CKiD) and nephrotic syndrome study network (NEPTUNE) cohorts. Nephrol Dial Transplant. 2017;32(6):983–90. https://doi.org/10.1093/ndt/gfw061.CrossRefPubMed

62.

Verbitsky M, Westland R, Perez A, Kiryluk K, Liu Q, Krithivasan P, et al. The copy number variation landscape of congenital anomalies of the kidney and urinary tract. Nat Genet. 2019;51(1):117–27. https://doi.org/10.1038/s41588-018-0281-y.CrossRefPubMed

63.

Wuttke M, Wong CS, Wuhl E, Epting D, Luo L, Hoppmann A, et al. Genetic loci associated with renal function measures and chronic kidney disease in children: the pediatric investigation for genetic factors linked with renal progression consortium. Nephrol Dial Transplant. 2016;31(2):262–9. https://doi.org/10.1093/ndt/gfv342.CrossRefPubMed

64.

Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305(15):1553–9. https://doi.org/10.1001/jama.2011.451.CrossRefPubMed

65.

Tangri N, Grams ME, Levey AS, Coresh J, Appel LJ, Astor BC, et al. Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis. JAMA. 2016;315(2):164–74. https://doi.org/10.1001/jama.2015.18202.CrossRefPubMedPubMedCentral

66.

• Winnicki E, McCulloch CE, Mitsnefes MM, Furth SL, Warady BA, Ku E. Use of the kidney failure risk equation to determine the risk of progression to end-stage renal disease in children with chronic kidney disease. JAMA Pediatr. 2018;172(2):174–80. https://doi.org/10.1001/jamapediatrics.2017.4083 This paper applies the kidney failure risk equation (KFRE) to participants in the CKiD study and proved adequate ability to discriminate the risk for ESRD; authors suggest the KFRE could be incorporated into routine clinical care of children with CKD.CrossRefPubMed

67.

Wong H, Mylrea K, Feber J, Drukker A, Filler G. Prevalence of complications in children with chronic kidney disease according to KDOQI. Kidney Int. 2006;70(3):585–90. https://doi.org/10.1038/sj.ki.5001608.CrossRefPubMed

68.

Mitsnefes M, Flynn J, Cohn S, Samuels J, Blydt-Hansen T, Saland J, et al. Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol. 2010;21(1):137–44. https://doi.org/10.1681/ASN.2009060609.CrossRefPubMedPubMedCentral

69.

Khandelwal P, Murugan V, Hari S, Lakshmy R, Sinha A, Hari P, et al. Dyslipidemia, carotid intima-media thickness and endothelial dysfunction in children with chronic kidney disease. Pediatr Nephrol. 2016;31(8):1313–20. https://doi.org/10.1007/s00467-016-3350-4.CrossRefPubMed

70.

Khurana M, Silverstein DM. Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease. Pediatr Nephrol. 2015;30(12):2073–84. https://doi.org/10.1007/s00467-015-3075-9.CrossRefPubMed

71.

Wesseling-Perry K, Salusky IB. Chronic kidney disease: mineral and bone disorder in children. Semin Nephrol. 2013;33(2):169–79. https://doi.org/10.1016/j.semnephrol.2012.12.017.CrossRefPubMedPubMedCentral

72.

Chen K, Didsbury M, van Zwieten A, Howell M, Kim S, Tong A, et al. Neurocognitive and educational outcomes in children and adolescents with CKD: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2018;13(3):387–97. https://doi.org/10.2215/CJN.09650917.CrossRefPubMedPubMedCentral

73.

Roberts MA. Commentary on the KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Nephrology (Carlton). 2014;19(1):53–5. https://doi.org/10.1111/nep.12168.CrossRef

74.

•• Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140(3). doi:https://doi.org/10.1542/peds.2017-1904. Updated national guidelines from the American Academy of Pediatrics regarding diagnosis and treatment of hypertension in children, with several guidelines specific to children with CKD which includes an expanded role for ambulatory blood pressure monitoring to screen for masked hypertension; also suggests more aggressive blood pressure targets for children with CKD than previously recommended, and provides a revised definition of left ventricular hypertrophy.

75.

Lurbe E, Agabiti-Rosei E, Cruickshank JK, Dominiczak A, Erdine S, Hirth A, et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens. 2016;34(10):1887–920. https://doi.org/10.1097/HJH.0000000000001039.CrossRefPubMed

76.

Dionne JM, Harris KC, Benoit G, Feber J, Poirier L, Cloutier L, et al. Hypertension Canada’s 2017 guidelines for the diagnosis, assessment, prevention, and treatment of pediatric hypertension. Can J Cardiol. 2017;33(5):577–85. https://doi.org/10.1016/j.cjca.2017.03.007.CrossRefPubMed

77.

Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, Santoro EP, et al. Losartan and enalapril are comparable in reducing proteinuria in children. Kidney Int. 2012;82(7):819–26. https://doi.org/10.1038/ki.2012.210.CrossRefPubMed

78.

• Fathallah-Shaykh SA. Proteinuria and progression of pediatric chronic kidney disease: lessons from recent clinical studies. Pediatr Nephrol. 2017;32(5):743–51. https://doi.org/10.1007/s00467-016-3448-8 Comprehensive review of the importance of proteinuria as a comorbidity, risk factor, and biomarker for progression in pediatric CKD.CrossRefPubMed

79.

van den Belt SM, Heerspink HJL, Gracchi V, de Zeeuw D, Wuhl E, Schaefer F, et al. Early proteinuria lowering by angiotensin-converting enzyme inhibition predicts renal survival in children with CKD. J Am Soc Nephrol. 2018;29(8):2225–33. https://doi.org/10.1681/ASN.2018010036.CrossRefPubMedPubMedCentral

80.

Nadeem S, Batisky DL. Aliskiren, the first direct renin inhibitor: assessing a role in pediatric hypertension and kidney diseases. Pediatr Nephrol. 2014;29(11):2105–11. https://doi.org/10.1007/s00467-013-2716-0.CrossRefPubMed

81.

Kelland EE, McAuley LM, Filler G. Are we ready to use aliskiren in children? Pediatr Nephrol. 2011;26(3):473–7. https://doi.org/10.1007/s00467-010-1702-z.CrossRefPubMed

82.

Wingen AM, Fabian-Bach C, Schaefer F, Mehls O. Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European study Group of Nutritional Treatment of chronic renal failure in childhood. Lancet. 1997;349(9059):1117–23.CrossRefPubMed

83.

Ajarmeh S, Er L, Brin G, Djurdjev O, Dionne JM. The effect of a multidisciplinary care clinic on the outcomes in pediatric chronic kidney disease. Pediatr Nephrol. 2012;27(10):1921–7. https://doi.org/10.1007/s00467-012-2209-6.CrossRefPubMed

84.

Filler G, Lipshultz SE. Why multidisciplinary clinics should be the standard for treating chronic kidney disease. Pediatr Nephrol. 2012;27(10):1831–4. https://doi.org/10.1007/s00467-012-2236-3.CrossRefPubMed

85.

American Academy of Pediatrics Section on Nephrology and American Society of Pediatric Nephrology. Choosing Wisely: Five Things Physicians and Patients Should Know. 2018. http://www.choosingwisely.org/societies/american-academy-of-pediatrics-section-on-nephrology-and-the-american-society-of-pediatric-nephrology/. Accessed 7/16/2018.

86.

Schinstock CA, Albright RC, Williams AW, Dillon JJ, Bergstralh EJ, Jenson BM, et al. Outcomes of arteriovenous fistula creation after the fistula first initiative. Clin J Am Soc Nephrol. 2011;6(8):1996–2002. https://doi.org/10.2215/CJN.11251210.CrossRefPubMedPubMedCentral

87.

Wartman SM, Rosen D, Woo K, Gradman WS, Weaver FA, Rowe V. Outcomes with arteriovenous fistulas in a pediatric population. J Vasc Surg. 2014;60(1):170–4. https://doi.org/10.1016/j.jvs.2014.01.050.CrossRefPubMed

88.

Kaur A, Davenport A. Hemodialysis for infants, children, and adolescents. Hemodial Int. 2014;18(3):573–82. https://doi.org/10.1111/hdi.12163.CrossRefPubMed

89.

Fischbach M, Edefonti A, Schroder C, Watson A. European pediatric Dialysis working G. Hemodialysis in children: general practical guidelines. Pediatr Nephrol. 2005;20(8):1054–66. https://doi.org/10.1007/s00467-005-1876-y.CrossRefPubMedPubMedCentral

90.

Chand DH, Valentini RP. International pediatric fistula first initiative: a call to action. Am J Kidney Dis. 2008;51(6):1016–24. https://doi.org/10.1053/j.ajkd.2008.02.309.CrossRefPubMed

Titel: Chronic Kidney Disease in Children: Risk-Based Stratification and Treatment
verfasst von: Darcy K. Weidemann, MD, MHS
Bradley A. Warady, MD
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Current Treatment Options in Pediatrics / Ausgabe 2/2019
Elektronische ISSN: 2198-6088
DOI: https://doi.org/10.1007/s40746-019-00150-x

Pediatric Hypertension

Pediatric Nephrology (BP Dixon and E Nehus, Section Editors)

Tactical Emergency Casualty Care (TECC) and the Pediatric Population

Disaster Medicine (MR Anderson and MW Dingeldein, Section Editors)

Gastrointestinal Dysmotility and the Implications for Respiratory Disease

Pulmonary (RP Boesch, Section Editor)

Improving Safety in Health Care: Beyond Standard Hospital-Acquired Conditions

Patient Safety (M Scanlon, Section Editor)

Patient Safety: What Is Working and Why?

Patient Safety (M Scanlon, Section Editor)

Resilience Engineering, Safety, and Implications for Pediatric Care

Patient Safety (M Scanlon, Section Editor)

Neu im Fachgebiet Pädiatrie

Vorsicht mit Glukokortikoiden bei Glomerulopathie

16.01.2025
Primäre Glomerulonephritiden
Nachrichten

Auch niedrig dosierte Glukokortikoide zur Behandlung einer primären Glomerulopathie lassen offenbar die Infektionsgefahr steigen. In einer US-Studie hing das Risiko vor allem mit der kombinierten Anwendung von Immunsuppressiva zusammen.

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

12.01.2025
Elektronische Patientenakte
Nachrichten

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Medikamente verändern wohl Nährstoffzusammensetzung der Muttermilch

Medikamente in Schwangerschaft und Stillzeit
Nachrichten

Einige Medikamente wie selektive Serotonin-Wiederaufnahmehemmer können offenbar die Makronährstoffzusammensetzung der Muttermilch verändern. Das birgt möglicherweise gesundheitliche Risiken für manche gestillte Kinder.

Kann man Gestationsdiabetes mit oralen Antidiabetika behandeln?

09.01.2025
Gestationsdiabetes
Nachrichten

Der Wunsch, Frauen mit Gestationsdiabetes eine orale Erstlinientherapie anbieten zu können, bleibt auch vorläufig ein Wunsch: Eine orale Stufentherapie hat sich in einer randomisierten Studie nicht als gleichwertig zu einer Insulintherapie erwiesen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Chronic Kidney Disease in Children: Risk-Based Stratification and Treatment

Abstract

Purpose of review

Recent findings

Summary

Weitere Artikel der Ausgabe 2/2019

Pediatric Hypertension

Tactical Emergency Casualty Care (TECC) and the Pediatric Population

Gastrointestinal Dysmotility and the Implications for Respiratory Disease

Improving Safety in Health Care: Beyond Standard Hospital-Acquired Conditions

Patient Safety: What Is Working and Why?

Resilience Engineering, Safety, and Implications for Pediatric Care

Neu im Fachgebiet Pädiatrie

Vorsicht mit Glukokortikoiden bei Glomerulopathie

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Medikamente verändern wohl Nährstoffzusammensetzung der Muttermilch

Kann man Gestationsdiabetes mit oralen Antidiabetika behandeln?

Update Pädiatrie

Springer Medizin

Abstract

Purpose of review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten